Patents by Inventor Vijaya Gopal

Vijaya Gopal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10806715
    Abstract: The current invention relates to development of new formulation containing gold nanoparticles (AuNPs) with bi-functional recombinant fusion proteins TRAF(C) for the delivery of anticancer drugs and nucleic acids to HER2+ cancers. Using the combinatorial approach, we designed gold nanoparticle-based targeted drug delivery system (TDDS) or (Au-TR-DX-si) by combining AuNPs with bi-functional recombinant fusion protein TRAF(C) (TR), doxorubicin (DX) and siRNA (si). The recombinant protein based gold nanoparticles formulations are stable and homogenous as revealed by several physicochemical studies. In addition, the engineered fusion protein TRAF (C) has the ability to target selectively to HER2+ receptors overexpressed in ovarian cancer cells (SK-OV-3).
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 20, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Rajesh Kotcherlakota, Sudip Mukherjee, Chitta Ranjan Patra, Vijaya Gopal
  • Publication number: 20190240186
    Abstract: The current invention relates to development of new formulation containing gold nanoparticles (AuNPs) with bi-functional recombinant fusion proteins TRAF(C) for the delivery of anticancer drugs and nucleic acids to HER2+ cancers. Using the combinatorial approach, we designed gold nanoparticle-based targeted drug delivery system (TDDS) or (Au-TR-DX-si) by combining AuNPs with bi-functional recombinant fusion protein TRAF(C) (TR), doxorubicin (DX) and siRNA (si). The recombinant protein based gold nanoparticles formulations are stable and homogenous as revealed by several physicochemical studies. In addition, the engineered fusion protein TRAF (C) has the ability to target selectively to HER2+ receptors overexpressed in ovarian cancer cells (SK-OV-3).
    Type: Application
    Filed: October 23, 2017
    Publication date: August 8, 2019
    Inventors: Rajesh Kotcherlakota, Sudip Mukherjee, Chitta Ranjan Patra, Vijaya Gopal
  • Publication number: 20160168126
    Abstract: The invention relates to pyrrolone compounds of the formula (I) wherein X, Ra, Rb, Rc, R1, R2 and R3 are as defined in the specification. Furthermore, the present invention relates to processes and intermediates for making compounds of formula (I), to herbicidal compositions comprising these compounds and to methods of using these compounds to control plant growth.
    Type: Application
    Filed: August 5, 2013
    Publication date: June 16, 2016
    Applicants: SYNGENTA LIMITED, SYNGENTA PARTICIPATIONS AG
    Inventors: Alan John Dowling, Timothy Robert Desson, William Guy Whittingham, Anne Jacqueline Dalencon, James Alan Morris, Jutta Elisabeth Boehmer, Mangala Phadte, Adrian Longstaff, Matthew Brian Hotson, Paul John De Fraine, Regis Jean Georges Mondiere, Shuji Hachisu, Alison Jane Thompson, Vijaya Gopal Gopalsamuthiram
  • Publication number: 20120027816
    Abstract: Provided herein is an impurity of eletriptan, eletriptan N-oxide, (R)-5-[2- (phenylsulfonypethyl]-3-[(1-methyl-2-pyrrolidinyl-N-oxide)methyl]-1H-indole, and a process for the preparation and isolation thereof. Provided further herein is a highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan N-oxide impurity, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan N-oxide impurity.
    Type: Application
    Filed: February 25, 2010
    Publication date: February 2, 2012
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Vijaya Gopal Kusumba, Sampath Kumar Sankineni, Praveen Kumar Neela, Nitin Sharadchandra Pradhan
  • Publication number: 20100285075
    Abstract: The present invention relates to novel hemioxalate salt of eletriptan, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention relates to solid forms of eletriptan hemioxalate, processes for preparation, pharmaceutical compositions, and method of treating thereof. The solid form of eletriptan hemioxalate is useful for preparing eletriptan free base or a pharmaceutically acceptable salt thereof, particularly eletriptan hydrobromide, in high purity. The present invention also provides a process for preparing substantially pure eletriptan hydrobromide using eletriptan hemioxalate.
    Type: Application
    Filed: December 17, 2008
    Publication date: November 11, 2010
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Vijaya Gopal Kusumba, Sampath Kumar Sankineni, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson